|Journal||Annals of the Rheumatic Diseases|
|State||Published - 1 Jun 2020|
Bibliographical noteFunding Information:
Competing interests FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica and 4P Pharma. RG reports personal fees from Pfizer, Cornerstones, Jannsen and Novartis. PK reports personal fees from GlaxoSmithKline, Sanofi-Aventis, Pfizer, Abbvie, Novartis Pharma, Eli Lilly and Bristol-Myers Squibb. AHJK reports grants from NIH (National Institutes of Health)/NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) and Rheumatology Research Foundation and personal fees from Exagen Diagnostics and GlaxoSmithKline. JAS reports grants from NIH/NIAID (National Institute of Allergy and Infectious Diseases)/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum.
- antirheumatic agents
- health services research